Abcellera Biologics Inc. Stock
€3.35
Your prediction
Abcellera Biologics Inc. Stock
Pros and Cons of Abcellera Biologics Inc. in the next few years
Pros
Cons
News
AbCellera Reports Q1 2024 Business Results
AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
AbCellera (Nasdaq: ABCL), Viking Global Investors (“Viking”), and ArrowMark Partners (“ArrowMark”) announced today that they have entered into a collaboration to advance new antibody drug programs
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
AbCellera (Nasdaq: ABCL) today announced new data on its T-cell engager (TCE) programs at the American Association for Cancer ResearchⓇ (AACR) Annual Meeting 2024 at the San Diego Convention